Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 11/20 | 0.50 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 10/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646061 | 0.84 | CCR2 (0.42) | ADRA1ADRD2HTR1AHTR2ADRD3 | |
| SCHEMBL3595429 | 0.84 | DRD2 (0.59) | DRD2HTR1AHTR2ADRD3DRD1 | |
| Hydrochloric Acid SCHEMBL7658854 | 0.83 | DRD2 (0.58) | DRD2HTR1AHTR2ADRD3DRD1 | |
| Hydrochloric Acid SCHEMBL7657963 | 0.83 | DRD2 (0.58) | DRD2HTR1AHTR2ADRD3DRD1 | |
| SCHEMBL27932651 | 0.81 | DRD2 (0.69) | DRD2HTR1AHTR2ADRD3DRD1 | |
| SCHEMBL23220401 | 0.81 | HTR2A (0.44) | ADRA1ADRD2HTR1AHTR2ADRD3 | |
| SCHEMBL13974994 | 0.79 | DRD3 (0.61) | ADRA1ADRD2HTR1ADRD3DRD1 | |
| SCHEMBL6198442 | 0.78 | SIGMAR1 (0.69) | DRD2 | |
| SCHEMBL4093709 | 0.77 | TLR9 (0.47) | DRD2 | |
| SCHEMBL13085465 | 0.77 | QDPR (0.59) | ADRA1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | ADRA1A 4/4885DRD2 1498/4885HTR1A 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.